These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 14962888)

  • 1. Prevention of coronary heart disease: is a cure too expensive?
    Cooke GA
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962888
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
    Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
    N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
    Lindgren P; Jönsson B; Yusuf S
    J Intern Med; 2004 May; 255(5):562-70. PubMed ID: 15078498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and economic considerations of coronary heart disease: a managed care approach. Proceedings based on presentations from two conferences, Cardiovascular Event Reduction: Defining the Role of HMG Therapy in Managed Care, held November 14-16, 1997 in Philadelphia, and Pharmacoeconomics & Outcomes Issues of Lipid Therapy, held November 5-7, 1997 in Orlando.
    Am J Manag Care; 1998 Apr; 4(4 Suppl):S168-233. PubMed ID: 10180343
    [No Abstract]   [Full Text] [Related]  

  • 5. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At what coronary risk level is it cost-effective to initiate cholesterol lowering drug treatment in primary prevention?
    Johannesson M
    Eur Heart J; 2001 Jun; 22(11):919-25. PubMed ID: 11428815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cost-utility analysis of clopidogrel in patients with non-ST-segment-elevation acute coronary syndromes in the UK.
    Karnon J; Bakhai A; Brennan A; Pandor A; Flather M; Warren E; Gray D; Akehurst R
    Int J Cardiol; 2006 May; 109(3):307-16. PubMed ID: 16026869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of statins. Health authorities must work with clinicians to target statins.
    Wakeman AP; Leach RH
    BMJ; 1997 Dec; 315(7122):1618. PubMed ID: 9437293
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care.
    Turner DA; Paul S; Stone MA; Juarez-Garcia A; Squire I; Khunti K
    Heart; 2008 Dec; 94(12):1601-6. PubMed ID: 18450843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of statin monotherapy and combination therapy with ezetimibe.
    Perkerson KA; Gillespie EL; Coleman CI
    Conn Med; 2005 Jan; 69(1):19-22. PubMed ID: 15736370
    [No Abstract]   [Full Text] [Related]  

  • 11. [Medicalization of the coronary patient].
    Jacobsen CD
    Tidsskr Nor Laegeforen; 1994 Oct; 114(26):3119. PubMed ID: 7974440
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
    Martens LL; Guibert R
    Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost-effectiveness analysis of aspirin versus oral anticoagulants after acute myocardial infarction in Italy -- equivalence of costs as a possible case for oral anticoagulants.
    Gianetti J; Gensini G; De Caterina R
    Thromb Haemost; 1998 Dec; 80(6):887-93. PubMed ID: 9869155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost effectiveness in the Danish health care of ezetemibe co-administration compared to simvastatin].
    Keiding H; Hildebrandt P; Alemao E; Davies GM
    Ugeskr Laeger; 2008 Jun; 170(26-32):2323-6. PubMed ID: 18570764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of coronary heart disease: incremental cost effectiveness raises issues.
    D'Avanzo WC
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962886
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost effectiveness of statins in coronary heart disease.
    Franco OH; Peeters A; Looman CW; Bonneux L
    J Epidemiol Community Health; 2005 Nov; 59(11):927-33. PubMed ID: 16234419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
    van Hout BA; Simoons ML
    Eur Heart J; 2001 May; 22(9):751-61. PubMed ID: 11350107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of coronary heart disease: data in table 2 could be shown more explicitly for better understanding.
    Messori A; Santarlasci B
    BMJ; 2004 Feb; 328(7436):405; author reply 405. PubMed ID: 14962887
    [No Abstract]   [Full Text] [Related]  

  • 19. [After coronary intervention. Which platelet inhibitor for whom?].
    Stiefelhagen P
    MMW Fortschr Med; 2007 Apr; 149(14):18-9. PubMed ID: 17668756
    [No Abstract]   [Full Text] [Related]  

  • 20. "Me-too" products--friend or foe?
    Lee TH
    N Engl J Med; 2004 Jan; 350(3):211-2. PubMed ID: 14724297
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.